Payment overview · 2025
General Payments
$275.25
13 reported records · 3 companies
Healthcare provider profile · identity verified
Karla Elizabeth Bracamonte Lopez
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · RALEIGH, NC · NPI 1053913020
Verified facts
What the public records show
CMS Open Payments records show Karla Elizabeth Bracamonte Lopez received $275.25 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 56.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $155.72 | 56.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $99.85 | 36.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.68 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $275.25 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $155.72 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $99.85 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 164 |
| Lisinopril | Lisinopril | 270 | 88 |
| Gabapentin | Gabapentin | 231 | 77 |
| Metformin Hcl | Metformin Hcl | 215 | 74 |
| Losartan Potassium | Losartan Potassium | 197 | 67 |
| Omeprazole | Omeprazole | 186 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 66 |
| Simvastatin | Simvastatin | 155 | 54 |
| Farxiga | Dapagliflozin Propanediol | 148 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 29 |
| Sertraline Hcl | Sertraline Hcl | 129 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 38 |
| Furosemide | Furosemide | 119 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 40 |
| Carvedilol | Carvedilol | 104 | 37 |
| Ezetimibe | Ezetimibe | 104 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 30 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Tradjenta | Linagliptin | 74 | 18 |
| Potassium Chloride | Potassium Chloride | 73 | 23 |
| Chlorthalidone | Chlorthalidone | 66 | 25 |
| Jardiance | Empagliflozin | 66 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 20 |
| Trulicity | Dulaglutide | 55 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 20 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | 17 |
| Lovastatin | Lovastatin | 41 | 15 |
| Eliquis | Apixaban | 40 | 13 |
| Atenolol | Atenolol | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 17 |
| Spironolactone | Spironolactone | 35 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 16 |
| Glipizide | Glipizide | 32 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 15 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275.25 · 13 records | GlaxoSmithKline, LLC. | REPATHA, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error